ReviewFrontiers in immunology2025
Nanomaterial assisted natural killer cell therapy.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomimetic Polymer-Based Nanomaterials for Immune-Responsive Hepatocellular Carcinoma Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising incidence of cancer has heightened interest in immune cell therapy, particularly the role of natural killer (NK) cells, which are essential components of the immune system. Their applications in tumor treatment have expanded significantly, especially with the incorporation of nanomaterials. This review comprehensively examines NK cell biology, encompassing aspects such as classification, distribution, receptor activation, and mechanisms of cytotoxicity. It also explores various NK cell therapies, including their sources, methods of acquisition, expansion techniques, Chimeric antigen receptor-Natural Killer cell (CAR-NK) technology, gene editing strategies, and combination therapies. Additionally, the review discusses the utilization of nanomaterials in NK cell therapy, focusing on nanoparticle-assisted immune regulation and the modulation of the tumor microenvironment. While NK cell therapy holds promise, CAR-NK technology presents certain limitations. The integration of nanomaterials offers potential strategies to enhance therapeutic efficacy. Future research should prioritize the optimization of NK cell therapy, address the limitations associated with CAR-NK technology, investigate the mechanisms of nanomaterials, and develop more effective nanomaterials to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.